At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 152 enrolled
Drug / intervention
Pazopanib Hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Pazopanib Hydrochloride for Recurrent Thyroid Gland Carcinoma and 12 related conditions. Completed, enrolled 152 participants across 22 sites in 5 countries.
Detailed Summary
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7, Thyroid Gland Anaplastic Carcinoma
CountriesAustralia, China, Singapore, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedFeb 2008
Primary CompletionDec 2018
Study CompletionAug 2019
TodayJul 2026
First PostedFeb 28, 2008
Enrollment StartFeb 22, 2008
Primary CompletionDec 21, 2018
Study CompletionAug 13, 2019
TodayJul 2, 2026
Enrollment to primary: 10.8 yearsPosted 18.3 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Pazopanib Hydrochloridedrug
Given PO